{"id":"pf-06700841","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"CEREBROVASCULAR ACCIDENT","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"NERVOUS SYSTEM DISORDER","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased levels of PF-06700841"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased levels of PF-06700841"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased levels of PF-06700841"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased levels of PF-06700841"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased levels of PF-06700841"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased levels of PF-06700841"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased levels of PF-06700841"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased levels of PF-06700841"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased levels of CYP3A4 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased levels of CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased levels of CYP2D6 substrates"}],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"9.2%","placeboRate":"","totalAtRisk":371,"totalAffected":34,"trialsReporting":7},{"effect":"Upper respiratory tract infection","drugRate":"6.8%","placeboRate":"","totalAtRisk":425,"totalAffected":29,"trialsReporting":7},{"effect":"Headache","drugRate":"5.7%","placeboRate":"","totalAtRisk":506,"totalAffected":29,"trialsReporting":10},{"effect":"Urinary tract infection","drugRate":"4.6%","placeboRate":"","totalAtRisk":461,"totalAffected":21,"trialsReporting":8},{"effect":"COVID-19","drugRate":"7.2%","placeboRate":"","totalAtRisk":250,"totalAffected":18,"trialsReporting":4},{"effect":"Nausea","drugRate":"4.9%","placeboRate":"","totalAtRisk":325,"totalAffected":16,"trialsReporting":7},{"effect":"Fatigue","drugRate":"3.4%","placeboRate":"","totalAtRisk":351,"totalAffected":12,"trialsReporting":5},{"effect":"Diarrhoea","drugRate":"2.5%","placeboRate":"","totalAtRisk":316,"totalAffected":8,"trialsReporting":5},{"effect":"Acne","drugRate":"2.2%","placeboRate":"","totalAtRisk":361,"totalAffected":8,"trialsReporting":7},{"effect":"Pruritus","drugRate":"3.2%","placeboRate":"","totalAtRisk":186,"totalAffected":6,"trialsReporting":4},{"effect":"Blood creatine phosphokinase increased","drugRate":"1.4%","placeboRate":"","totalAtRisk":419,"totalAffected":6,"trialsReporting":8},{"effect":"Bronchitis","drugRate":"2.4%","placeboRate":"","totalAtRisk":209,"totalAffected":5,"trialsReporting":4},{"effect":"Hypertension","drugRate":"1.9%","placeboRate":"","totalAtRisk":266,"totalAffected":5,"trialsReporting":5},{"effect":"Alanine aminotransferase increased","drugRate":"3.5%","placeboRate":"","totalAtRisk":144,"totalAffected":5,"trialsReporting":3},{"effect":"Gastroenteritis","drugRate":"1.7%","placeboRate":"","totalAtRisk":241,"totalAffected":4,"trialsReporting":4},{"effect":"Cystitis","drugRate":"2.0%","placeboRate":"","totalAtRisk":197,"totalAffected":4,"trialsReporting":3},{"effect":"Arthralgia","drugRate":"2.6%","placeboRate":"","totalAtRisk":151,"totalAffected":4,"trialsReporting":3},{"effect":"Crohn's disease","drugRate":"5.1%","placeboRate":"","totalAtRisk":79,"totalAffected":4,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"3.7%","placeboRate":"","totalAtRisk":107,"totalAffected":4,"trialsReporting":2},{"effect":"Abdominal discomfort","drugRate":"8.5%","placeboRate":"","totalAtRisk":47,"totalAffected":4,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"1.4%","placeboRate":"","totalAtRisk":216,"totalAffected":3,"trialsReporting":4},{"effect":"Back pain","drugRate":"1.9%","placeboRate":"","totalAtRisk":162,"totalAffected":3,"trialsReporting":3},{"effect":"Anaemia","drugRate":"1.3%","placeboRate":"","totalAtRisk":229,"totalAffected":3,"trialsReporting":4},{"effect":"Dermatitis atopic","drugRate":"2.8%","placeboRate":"","totalAtRisk":109,"totalAffected":3,"trialsReporting":3},{"effect":"Oral herpes","drugRate":"2.1%","placeboRate":"","totalAtRisk":144,"totalAffected":3,"trialsReporting":3},{"effect":"Aspartate aminotransferase increased","drugRate":"3.1%","placeboRate":"","totalAtRisk":97,"totalAffected":3,"trialsReporting":2},{"effect":"SARS-CoV-2 test positive","drugRate":"3.8%","placeboRate":"","totalAtRisk":79,"totalAffected":3,"trialsReporting":1},{"effect":"Neutropenia","drugRate":"5.0%","placeboRate":"","totalAtRisk":60,"totalAffected":3,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"0.9%","placeboRate":"","totalAtRisk":234,"totalAffected":2,"trialsReporting":5},{"effect":"Urticaria","drugRate":"1.2%","placeboRate":"","totalAtRisk":172,"totalAffected":2,"trialsReporting":3},{"effect":"Rash","drugRate":"0.9%","placeboRate":"","totalAtRisk":229,"totalAffected":2,"trialsReporting":4},{"effect":"Pharyngitis","drugRate":"1.4%","placeboRate":"","totalAtRisk":144,"totalAffected":2,"trialsReporting":3},{"effect":"Pneumonia","drugRate":"3.3%","placeboRate":"","totalAtRisk":60,"totalAffected":2,"trialsReporting":1},{"effect":"Hepatic enzyme increased","drugRate":"3.3%","placeboRate":"","totalAtRisk":60,"totalAffected":2,"trialsReporting":1},{"effect":"Hidradenitis","drugRate":"2.1%","placeboRate":"","totalAtRisk":95,"totalAffected":2,"trialsReporting":2},{"effect":"Sinusitis","drugRate":"4.3%","placeboRate":"","totalAtRisk":47,"totalAffected":2,"trialsReporting":1},{"effect":"Folliculitis","drugRate":"0.4%","placeboRate":"","totalAtRisk":228,"totalAffected":1,"trialsReporting":4},{"effect":"Dry skin","drugRate":"1.0%","placeboRate":"","totalAtRisk":102,"totalAffected":1,"trialsReporting":2},{"effect":"Cough","drugRate":"0.3%","placeboRate":"","totalAtRisk":290,"totalAffected":1,"trialsReporting":6},{"effect":"Insomnia","drugRate":"0.6%","placeboRate":"","totalAtRisk":181,"totalAffected":1,"trialsReporting":3},{"effect":"Vomiting","drugRate":"0.7%","placeboRate":"","totalAtRisk":147,"totalAffected":1,"trialsReporting":2},{"effect":"Oedema peripheral","drugRate":"1.6%","placeboRate":"","totalAtRisk":62,"totalAffected":1,"trialsReporting":2},{"effect":"Conjunctivitis","drugRate":"0.9%","placeboRate":"","totalAtRisk":109,"totalAffected":1,"trialsReporting":3},{"effect":"Herpes zoster","drugRate":"1.2%","placeboRate":"","totalAtRisk":85,"totalAffected":1,"trialsReporting":2},{"effect":"Ulcerative keratitis","drugRate":"2.7%","placeboRate":"","totalAtRisk":37,"totalAffected":1,"trialsReporting":1},{"effect":"Administration site warmth","drugRate":"2.7%","placeboRate":"","totalAtRisk":37,"totalAffected":1,"trialsReporting":1},{"effect":"Application site pain","drugRate":"2.7%","placeboRate":"","totalAtRisk":37,"totalAffected":1,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"2.7%","placeboRate":"","totalAtRisk":37,"totalAffected":1,"trialsReporting":1},{"effect":"Pain","drugRate":"2.7%","placeboRate":"","totalAtRisk":37,"totalAffected":1,"trialsReporting":1},{"effect":"Laryngitis","drugRate":"1.2%","placeboRate":"","totalAtRisk":84,"totalAffected":1,"trialsReporting":2}],"contraindications":["CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other"],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Participants who are between the ages of 18 and 75 years, inclusive","Paediatric use":"Not mentioned","Renal impairment":"Eligibility criteria: * •Normal, Severe, Moderate and Mild renal function at 2 Screening visits.","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06700841","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:55.546371+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:02.644362+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:36:55.567787+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06700841","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:03.538328+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5303356/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:04.341381+00:00"}},"offLabel":[],"timeline":[],"brandName":"Pf-06700841","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"PF-06700841's mechanism of action is not specified in available literature. This lack of information makes it challenging to discuss the drug's technical details. Further research is necessary to elucidate the drug's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06700841","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06700841","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:32.063587+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Deucravacitinib","company":"Unknown","advantage":"Selective allosteric tyrosine kinase 2 inhibition, improved safety profile"},{"name":"Brepocitinib (PF-06700841)","company":"Pfizer","advantage":"Dual TYK2/JAK1 inhibitor, targets the active site in the catalytic domain"},{"name":"Ropsacitinib (PF-06826647)","company":"Pfizer","advantage":"Dual TYK2/JAK2 inhibitor, targets the active site in the catalytic domain"},{"name":"Tofacitinib","company":"Unknown","advantage":"JAK1/2/3 inhibitor, targets the catalytic domain"}],"genericName":"pf-06700841","indications":{"approved":[{"name":"Multiple Sclerosis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05437263","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Priovant Therapeutics, Inc.","startDate":"2022-10-31","conditions":"Dermatomyositis","enrollment":241},{"nctId":"NCT05523765","phase":"PHASE2","title":"A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis","status":"COMPLETED","sponsor":"Priovant Therapeutics, Inc.","startDate":"2022-11-14","conditions":"Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis","enrollment":26},{"nctId":"NCT03395184","phase":"PHASE2","title":"Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-02-02","conditions":"Crohn's Disease","enrollment":244},{"nctId":"NCT03845517","phase":"PHASE2","title":"A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-18","conditions":"Systemic Lupus Erythematosus","enrollment":350},{"nctId":"NCT05076006","phase":"PHASE2","title":"Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia","status":"COMPLETED","sponsor":"Emma Guttman","startDate":"2021-05-19","conditions":"Cicatricial Alopecia","enrollment":50},{"nctId":"NCT04260464","phase":"PHASE1","title":"Renal Impairment Study of PF-06700841","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-03","conditions":"Healthy Volunteer, Renal Impairment","enrollment":30},{"nctId":"NCT04092452","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-12-02","conditions":"Acne Inversa","enrollment":194},{"nctId":"NCT02958865","phase":"PHASE2","title":"Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-02-03","conditions":"Ulcerative Colitis","enrollment":319},{"nctId":"NCT03850483","phase":"PHASE2","title":"Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-08","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT03715829","phase":"PHASE2","title":"A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-26","conditions":"Active Non-segmental Vitiligo","enrollment":366},{"nctId":"NCT03963401","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-13","conditions":"Psoriatic Arthritis","enrollment":219},{"nctId":"NCT03903822","phase":"PHASE2","title":"Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-05-13","conditions":"Atopic Dermatitis","enrollment":292},{"nctId":"NCT04580797","phase":"PHASE1","title":"Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-10-02","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT04267250","phase":"PHASE1","title":"Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-24","conditions":"Healthy Female Volunteers","enrollment":18},{"nctId":"NCT02974868","phase":"PHASE2","title":"Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-12-15","conditions":"Alopecia Areata","enrollment":142},{"nctId":"NCT04090047","phase":"PHASE1","title":"A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-24","conditions":"Heathy Participants","enrollment":12},{"nctId":"NCT03916250","phase":"PHASE1","title":"Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-23","conditions":"Healthy","enrollment":20},{"nctId":"NCT03765554","phase":"PHASE1","title":"Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-07","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT02969018","phase":"PHASE2","title":"Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-12","conditions":"Chronic Plaque Psoriasis","enrollment":212},{"nctId":"NCT03770039","phase":"PHASE1","title":"Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-10","conditions":"Healthy Male Subjects","enrollment":6},{"nctId":"NCT03656952","phase":"PHASE1","title":"A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-05","conditions":"Healthy","enrollment":33},{"nctId":"NCT03236493","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-16","conditions":"Healthy","enrollment":8},{"nctId":"NCT02310750","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-11","conditions":"Plaque Psoriasis","enrollment":96}],"_emaApprovals":[{"date":"","name":"PF-06700841","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5303356","moleculeType":null,"molecularWeight":"561.62"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5303356","pubchemSID":"381132240"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 May 24","pmid":"38892802","title":"Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.","journal":"Journal of clinical medicine"},{"date":"2023 May","pmid":"37096862","title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis.","journal":"Expert opinion on investigational drugs"},{"date":"2023 Jan","pmid":"36747955","title":"Hyperin promotes proliferation, migration, and invasion of HTR-8/SVneo trophoblast cells via activation of JAK1/STAT3 pathway in recurrent spontaneous abortions.","journal":"Heliyon"},{"date":"2023 Feb","pmid":"36592300","title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.","journal":"Dermatology and therapy"},{"date":"2023 Jan-Feb","pmid":"36519621","title":"Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.","journal":"Journal of cutaneous medicine and surgery"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Unknown","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":18,"withResults":10},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:32.063587+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}